CN114470101A - Traditional Chinese medicine composition and preparation method thereof, and oral preparation containing the same - Google Patents
Traditional Chinese medicine composition and preparation method thereof, and oral preparation containing the same Download PDFInfo
- Publication number
- CN114470101A CN114470101A CN202210250536.3A CN202210250536A CN114470101A CN 114470101 A CN114470101 A CN 114470101A CN 202210250536 A CN202210250536 A CN 202210250536A CN 114470101 A CN114470101 A CN 114470101A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- medicine composition
- traditional chinese
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种中药组合物及其制备方法、含其的口服剂,所述中药组合物中按生料计各原料的质量比如下:见血清1000:决明子100~2000:山楂10~1000:枸杞5~500;本发明提供的中药组合物中有效成分纯度高,作用过程温和,见效快,副作用小。
The invention discloses a traditional Chinese medicine composition, a preparation method thereof, and an oral preparation containing the same. The mass ratio of each raw material in the traditional Chinese medicinal composition based on raw meal is as follows: see serum 1000: cassia seed 100-2000: hawthorn 10-1000 : Lycium barbarum 5-500; the traditional Chinese medicine composition provided by the invention has high purity of active ingredients, mild action process, quick effect and little side effect.
Description
技术领域technical field
本发明属于中药领域,特别是涉及一种中药组合物及其制备方法、含其的口服剂。The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method thereof, and an oral preparation containing the same.
背景技术Background technique
见血清Liparis nervosa(Thunb)Lindl.属于兰科羊耳蒜属植物,地生草本,又称“岩芋”、“黑蓝”、“矮胖儿”、“羊耳蒜”等,广泛分布于我国云、贵、川、两广等地,是我国传统民间药用植物,其性凉,味苦,且具有凝血、抗炎、抑菌、抗氧化等药理活性,可用于清热解毒、凉血、止血等。See Serum Liparis nervosa (Thunb) Lindl. It belongs to the Orchidaceae Sheep's ear allium, a terrestrial herb, also known as "rock taro", "black blue", "chumpty child", "sheep ear garlic", etc. It is widely distributed in It is a traditional folk medicinal plant in my country, such as Yunnan, Guizhou, Sichuan, Guangdong and Guangxi. Hemostasis, etc.
目前,国内外针对见血清的研究主要集中在其化学成分的提取、分析以及一些活性成分抗肿瘤、抗菌、抗炎、抗氧化、止血作用的药理活性研究上;但未见其应用于降血压、降血脂临床治疗。At present, domestic and foreign researches on serotonin mainly focus on the extraction and analysis of its chemical components and the pharmacological activities of some active components in anti-tumor, antibacterial, anti-inflammatory, anti-oxidative, and hemostatic effects; , Clinical treatment of hypolipidemic.
高血压如今是非常常见的一种疾病,大多发生在中老年人身上,但是随着生活节奏加快、压力增大等,很多年轻人也患上了高血压,高血压是内科常见的一种心血管疾病,导致它的原因有很多,本质上是遗传和环境两方面。High blood pressure is a very common disease nowadays, most of which occur in middle-aged and elderly people. However, with the accelerated pace of life and increased pressure, many young people also suffer from high blood pressure. High blood pressure is a common heart disease in internal medicine. Vascular disease, which has many causes, is essentially both genetic and environmental.
高血脂,一般多集中在老年人患者当中,老年人血脂高于正常的规定范围,就容易形成这类疾病,高血脂包括高胆固醇血症、高甘油三脂血症及复合性高脂血症;血脂过高很容易导致血压高,高血脂会使人体形成动脉粥样硬化,导致心肌功能的紊乱,还会导致冠心病,当人体因长期高血脂形成动脉粥样硬化之后,会使冠状动脉的血流量变小、血管腔内变窄,心肌的注血量也会减少,造成心肌缺血,导致心绞痛,形成冠心病;高血脂会导致肝部功能损伤,长期的血脂高会导致脂肪肝,肝动脉粥样硬化后受到损害,肝小叶也同样受到损伤,从而导致结构发生变化,导致肝功能受到损害;高血脂容易形成血管硬化,形成粥样硬化之后,大量的脂类物质蛋白在血浆中沉积,降低血流的速度,并且通过氧化作用后酸败,沉积在动脉管内皮上,长期的粘附在血管壁上,会损伤动脉血管皮,造成血管硬化。Hyperlipidemia is generally concentrated in elderly patients. The elderly's blood lipids are higher than the normal prescribed range, and it is easy to form such diseases. Hyperlipidemia includes hypercholesterolemia, hypertriglyceridemia and complex hyperlipidemia ; High blood lipids can easily lead to high blood pressure, high blood lipids will cause the human body to form atherosclerosis, lead to myocardial dysfunction, and also lead to coronary heart disease. When the human body forms atherosclerosis due to long-term high blood lipids, it will cause coronary artery disease. The blood flow decreases, the vascular cavity narrows, and the amount of blood injected into the myocardium will also decrease, resulting in myocardial ischemia, angina pectoris, and coronary heart disease; high blood lipids can lead to liver damage, and long-term high blood lipids can lead to fatty liver , hepatic atherosclerosis is damaged, and the hepatic lobules are also damaged, resulting in structural changes and damage to liver function; hyperlipidemia is easy to form vascular sclerosis, after the formation of atherosclerosis, a large amount of lipids and proteins in the plasma It is deposited in the medium, reducing the speed of blood flow, and after oxidation, it becomes rancid and deposited on the endothelium of the arterial tube. It will adhere to the blood vessel wall for a long time, which will damage the arterial blood vessel skin and cause vascular sclerosis.
对于高血压、高血脂目前主要治疗方法有运动治疗、饮食治疗、中医调理、药物治疗等方法,不过运动治疗、饮食治疗、中医调理见效慢,受很多因素的制约而得不到理想效果,西药降压药物效果显著,但多数具有一定的副作用,对心、肾等脏器有一定程度的伤害。At present, the main treatment methods for hypertension and hyperlipidemia include exercise therapy, diet therapy, traditional Chinese medicine conditioning, and drug therapy. Antihypertensive drugs are effective, but most of them have certain side effects, which can damage the heart, kidneys and other organs to a certain extent.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种中药组合物、含其的口服剂,该中药组合物及含其的口服剂,能有效降低人体血压和血脂,且作用过程温和、副作用小。The purpose of the present invention is to provide a traditional Chinese medicine composition and an oral preparation containing the traditional Chinese medicine composition, which can effectively reduce blood pressure and blood lipids of human body, and have mild action process and few side effects.
本发明的目的还在于提供一种中药组合物的制备方法,该方法能有效提取见血清中有效成分—总生物碱及决明子中的蒽醌类成分、山楂和枸杞的全成分,减少了无效成分和刺激性成分,使中药组合物的作用过程更温和,副作用减小,降血压、降血脂效果提高。The object of the present invention is also to provide a preparation method of a traditional Chinese medicine composition, which can effectively extract the active ingredients in the serum—total alkaloids and anthraquinones in cassia seeds, hawthorn and wolfberry, and reduce the ineffective ingredients. and irritating ingredients, so that the action process of the traditional Chinese medicine composition is milder, the side effects are reduced, and the blood pressure lowering and blood lipid lowering effects are improved.
本发明所采用的技术方案是,中药组合物的制备方法,具体包括以下步骤:The technical scheme adopted in the present invention is that the preparation method of the traditional Chinese medicine composition specifically comprises the following steps:
步骤1,将干燥见血清清洗、除杂后过筛,使用酸性极性溶液反复提取,合并提取液用稀碱溶液中和使体系pH=6.5~7.5,真空回收极性溶剂得到浸膏;In
步骤2,用水分散浸膏后加乙醇沉淀24h,过滤,滤液回收乙醇后使用氯仿对醇提物进行萃取,对萃取组分进行分离纯化得到见血清提取物;
步骤3,分别提取决明子提取物、山楂提取物和枸杞提取物,将见血清提取物与各提取物混合得到中药组合物。Step 3, extract the cassia seed extract, the hawthorn extract and the wolfberry extract respectively, and mix the serum extract with each of the extracts to obtain a traditional Chinese medicine composition.
进一步的,所述步骤1中反复提取的具体过程如下:Further, the specific process of repeatedly extracting in the
使用酸性极性溶剂在25℃~90℃下提取1~10h,再使用酸性极性溶剂在25℃~90℃下提取0.5~1.5h,所述酸性极性溶剂的pH=1.0~3.0。Use an acidic polar solvent for extraction at 25°C to 90°C for 1 to 10 hours, and then use an acidic polar solvent for extraction at 25°C to 90°C for 0.5 to 1.5 hours. The pH of the acidic polar solvent is 1.0 to 3.0.
进一步的,所述步骤2中分离纯化过程如下:Further, in the described
采用硅胶柱进行层析,使用CHCl3/MeOH为洗脱体系进行梯度洗脱,分部收集得到活性化合物,即为见血清提取物。The silica gel column was used for chromatography, and CHCl 3 /MeOH was used as the elution system for gradient elution, and the active compounds were collected by fractions, which was the serum extract.
进一步的,提取决明子提取物的过程如下:Further, the process of extracting the cassia seed extract is as follows:
将决明子干燥打粉后,使用15%的硫酸溶液润湿5d,然后使用氯仿回流提取3h,稍放冷后抽滤,分离出提取液中的酸水层,使用蒸馏水反复洗涤得到氯仿提取液;The cassia seeds were dried and powdered, wetted with 15% sulfuric acid solution for 5 days, then extracted with chloroform under reflux for 3 hours, allowed to cool for a while, and filtered with suction to separate the acid water layer in the extract, and repeatedly washed with distilled water to obtain the chloroform extract;
使用pH=8.0的缓冲液将氯仿提取液反复萃取得到萃余相,用0.2%的NaOH溶液反复萃取萃余相;Use pH=8.0 buffer to repeatedly extract the chloroform extract to obtain the raffinate phase, and repeatedly extract the raffinate phase with 0.2% NaOH solution;
混合NaOH萃取液,在搅拌条件下滴加盐酸至体系pH=3,待沉淀完全析出后抽滤,使用蒸馏水将沉淀物洗涤至中性,干燥;Mix the NaOH extract, add hydrochloric acid dropwise under stirring until the pH of the system is 3, after the precipitation is completely separated out, suction filter, use distilled water to wash the precipitate to neutrality, and dry;
使用丙酮溶解沉淀物,采用硅胶柱进行层析,使用石油醚-乙酸乙酯洗脱,收集黄色色带,合并馏分、浓缩、放置析晶,收集晶体,重复柱层析分离,使用丙酮重结晶,得到决明子提取物。Use acetone to dissolve the precipitate, use silica gel column for chromatography, use petroleum ether-ethyl acetate to elute, collect yellow bands, combine fractions, concentrate, stand for crystallization, collect crystals, repeat column chromatography separation, use acetone for recrystallization , to obtain cassia seed extract.
进一步的,所述山楂提取物、枸杞提取物的提取过程如下:Further, the extraction process of the hawthorn extract and the wolfberry extract is as follows:
使用蒸馏水浸泡山楂或枸杞30min,加热至沸腾后保持微沸60min,压滤后在山楂或枸杞中加蒸馏水再次煎煮30min,合并煎出液,真空浓缩后置50℃水浴锅中缓慢浓缩得到山楂提取物或枸杞提取物。Soak hawthorn or wolfberry in distilled water for 30min, heat to boiling and keep slightly boiling for 60min, add distilled water to hawthorn or wolfberry and decoct again for 30min after pressure filtration, combine the decoction liquid, concentrate in 50℃ water bath and slowly concentrate to obtain hawthorn extract or wolfberry extract.
中药组合物,按生料计各原料的质量比如下:见血清1000:决明子100~2000:山楂10~1000:枸杞5~500。For the traditional Chinese medicine composition, the quality ratio of each raw material based on raw meal is as follows: see serum 1000: cassia seed 100-2000: hawthorn 10-1000: wolfberry 5-500.
含有中药组合物的口服剂,所述口服剂为片剂或胶囊。An oral preparation containing a traditional Chinese medicine composition, the oral preparation is a tablet or a capsule.
进一步的,由各物质按以下质量比制成:中药组合物10:糊精3:羧甲基纤维素钠1:羟丙基纤维素钠2:硬脂酸镁0.2。Further, it is prepared by the following mass ratios of various substances: Chinese medicine composition 10: dextrin 3: sodium carboxymethyl cellulose 1: sodium hydroxypropyl cellulose 2: magnesium stearate 0.2.
进一步的,所述口服剂为胶囊,由各物质按以下质量比制成:中药组合物10:糊精5:羧甲基纤维素钠1:硬脂酸镁0.2。Further, the oral preparation is a capsule, which is prepared by the following mass ratios of various substances: traditional Chinese medicine composition 10: dextrin 5: sodium carboxymethyl cellulose 1: magnesium stearate 0.2.
本发明的有益效果是:本发明实施例采用见血清与决明子、枸杞、山楂的提取物,经处理后压片或制成胶囊,可用于高血压、高血脂的治疗,能够标本兼治,且起效快、疗程短、毒副作用小。The beneficial effects of the present invention are as follows: in the embodiment of the present invention, extracts of cassia seed, medlar, and hawthorn are used, which are processed into tablets or made into capsules, which can be used for the treatment of hypertension and hyperlipidemia. Fast effect, short course of treatment, and less toxic and side effects.
附图说明Description of drawings
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to explain the embodiments of the present invention or the technical solutions in the prior art more clearly, the following briefly introduces the accompanying drawings that need to be used in the description of the embodiments or the prior art. Obviously, the accompanying drawings in the following description are only These are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained according to these drawings without creative efforts.
图1是中药组合物1对胰脂肪酶活性的作用效果图。Fig. 1 is a graph showing the effect of traditional
图2是油酸对HepG2细胞的作用效果图。Figure 2 is a graph showing the effect of oleic acid on HepG2 cells.
图3是中药组合物对甘油三酯合成的作用效果图。Fig. 3 is the effect diagram of the effect of traditional Chinese medicine composition on triglyceride synthesis.
图4是中药组合物对脂类合成的作用效果图。Figure 4 is a graph showing the effect of traditional Chinese medicine compositions on lipid synthesis.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.
本申请中用于降血压、降血脂的中药组合物由各原料的质量比如下:见血清1000:决明子100~2000:山楂10~1000:枸杞5~500,各原料的质量都是按生料计。The quality ratio of each raw material for the traditional Chinese medicine composition for lowering blood pressure and blood lipid in this application is as follows: see Serum 1000: Cassia 100-2000: Hawthorn 10-1000: Lycium barbarum 5-500, the quality of each raw material is based on raw materials count.
实施例1Example 1
中药组合物的制备过程如下:The preparation process of the traditional Chinese medicine composition is as follows:
步骤1,取干燥的见血清1000g,清洗除杂,粉碎后过20目筛,使用体积为见血清质量20倍的pH=1.0~3.0的酸性极性溶剂在25℃~90℃下提取1~10h,再用10倍的酸性极性溶剂同条件下提取0.5~1.5h,合并提取液,用稀碱液中和使体系pH=6.5~7.5,真空回收极性溶剂得到浸膏;
使用适量水分散浸膏,加乙醇至其体积浓度为80%~90%,搅拌均匀后沉淀24h、过滤,滤液回收乙醇后分别使用氯仿、乙酸乙酯对过滤后的醇提物进行萃取,再对萃取后的组分进行分离纯化得到系列提取物;Use an appropriate amount of water to disperse the extract, add ethanol to the volume concentration of 80% to 90%, stir evenly, precipitate for 24 hours, filter, recover ethanol from the filtrate, use chloroform and ethyl acetate to extract the filtered alcohol extract, and then The extracted components are separated and purified to obtain a series of extracts;
具体分离纯化过程如下:The specific separation and purification process is as follows:
氯仿部位采用硅胶柱进行层析,用CHCl3/MeOH为洗脱体系进行梯度洗脱,分部收集得到活性化合物Liparis alkaloid(总生物碱),包括提取物1、提取物2和提取物3;Chloroform part was chromatographed with silica gel column, gradient elution was carried out with CHCl 3 /MeOH as elution system, and the active compound Liparis alkaloid (total alkaloid) was obtained by fractional collection, including
乙酸乙酯部位采用硅胶柱进行层析,用CHCl3/MeOH为洗脱体系进行梯度洗脱,分部收集得到活性化合物Phenolic glycosides(酚糖苷),包括提取物4、提取物5和提取物6;The ethyl acetate part was chromatographed on a silica gel column, and the gradient elution was carried out with CHCl 3 /MeOH as the elution system, and the active compounds Phenolic glycosides (phenolic glycosides) were obtained by fractional collection, including extract 4, extract 5 and extract 6 ;
将活性化合物Liparis alkaloid、活性化合物Phenolic glycosides分别真空浓缩至干噪,用少量纯净水分散得到浸膏I和浸膏II。The active compound Liparis alkaloid and the active compound Phenolic glycosides were concentrated in vacuum to dryness, respectively, and dispersed with a small amount of purified water to obtain extract I and extract II.
步骤2,分别提取决明子提取物、山楂提取物、枸杞提取物;
步骤3,将浸膏I、明子提取物、山楂提取物、枸杞提取物混合复配得到中药组合物1,将浸膏II、明子提取物、山楂提取物、枸杞提取物混合复配得到中药组合物2。Step 3: Mixing and compounding the extract I, the extract of Mingzi, the hawthorn extract, and the extract of Lycium barbarum to obtain the traditional
所述步骤1中提取的时间较短时,见血清中的有效物质尚未完全溶出,浸膏的产率较低,会浪费见血清资源,提取的时间较长时,有效物质的溶出早已达到平衡,延长时间只会增加人力、物力成本,同时浸膏中的杂质浸出量也会增加,降低了提取效果。When the extraction time in the
同时使用极性溶液提取的温度较低时不利于有效物质溶出,温度较高时可能会破坏见血清中的有效成分,影响见血清提取物的质量。At the same time, when the temperature of polar solution extraction is low, it is not conducive to the dissolution of effective substances. When the temperature is high, it may destroy the effective components in the serum and affect the quality of the serum extract.
步骤1中使用乙醇提取时乙醇的体积浓度过小,达不到去除大部分醇不溶性杂质的目的,体积浓度过大会增加乙醇的用量,形成浪费;沉淀时间过短,使得见血清中的杂质未充分沉降,杂质去除不完全,时间过长,形成设备、人力浪费。In
决明子提取物的提取过程如下:The extraction process of cassia seed extract is as follows:
将决明子干燥打粉,称取200g置于1000mL~20000mL圆底烧瓶或提取罐中,加入200mL~4000mL体积浓度为15%的硫酸溶液润湿5d,然后再加入500mL~10000mL氯仿回流提取3h,稍放冷后抽滤,丢掉残渣,将氯仿提取液转入分液漏斗/分液器中,待分出酸水层后,用75mL~1500mL蒸馏水反复洗涤氯仿提取液3次得到氯仿提取液。Dry and powder the Cassia seeds, weigh 200g and place it in a 1000mL~20000mL round-bottom flask or extraction tank, add 200mL~4000mL of sulfuric acid solution with a volume concentration of 15% to wet for 5 days, then add 500mL~10000mL of chloroform to reflux for extraction for 3 hours, and let it sit for a while. After cooling, suction filtration, discard the residue, transfer the chloroform extract into a separating funnel/separator, and after separating the acid water layer, repeatedly wash the chloroform extract 3 times with 75 mL to 1500 mL of distilled water to obtain the chloroform extract.
将氯仿提取液置于100mL~20000mL分液漏斗/分液器中,用150~3000mL pH=8.0的缓冲液反复萃取5次后得到萃余相,将萃余相置于1000mL~20000mL分液漏斗/分液器中,用200mL~4000mL体积浓度为0.2%NaOH反复萃取4次。Place the chloroform extract in a 100mL~20000mL separatory funnel/separator, repeat the extraction with 150~3000mL pH=8.0 buffer for 5 times to obtain a raffinate phase, and place the raffinate phase in a 1000mL~20000mL separatory funnel In the / separator, repeatedly extract 4 times with 200mL-4000mL volume concentration of 0.2% NaOH.
混合氢氧化钠萃取液并放置于1000mL~20000mL烧杯/反应釜中,在搅拌下滴加盐酸至pH=3.0,待沉淀析出完全后,抽滤,用少量蒸馏水洗涤呈中性,沉淀物自然干燥备用。Mix the sodium hydroxide extract and place it in a 1000mL~20000mL beaker/reactor, add hydrochloric acid dropwise with stirring to pH=3.0, after the precipitation is complete, filter with suction, wash with a small amount of distilled water to be neutral, and the precipitate is naturally dried spare.
称取1g沉淀物放在蒸发皿中,加适量丙酮溶解,加25g柱层析用的硅胶,搅拌均匀,通风橱挥干备用。Weigh 1 g of the precipitate and place it in an evaporating dish, add an appropriate amount of acetone to dissolve, add 25 g of silica gel for column chromatography, stir evenly, and evaporate to dryness in a fume hood for later use.
称取200g硅胶加石油醚-乙酸乙酯(28:1)搅拌均匀,装于层析柱中,干法上样,用石油醚-乙酸乙酯洗脱,收集黄色色带,每份20mL,以硅胶G板检查各馏份,合并馏份,稍稍浓缩,放置析晶,收集晶体,再重复一次柱层析分离,用分析纯的丙酮重结晶,得决明子提取物。Weigh 200 g of silica gel plus petroleum ether-ethyl acetate (28:1), stir evenly, put it in a chromatography column, dry sample, elute with petroleum ether-ethyl acetate, collect yellow color bands, each 20 mL, Check each fraction with a silica gel G plate, combine the fractions, concentrate a little, stand for crystallization, collect the crystals, repeat the separation by column chromatography again, and recrystallize with analytically pure acetone to obtain the cassia extract.
山楂提取物的制备过程如下:The preparation process of hawthorn extract is as follows:
取山楂100g置烧杯中,加适量蒸馏水浸没药材,浸泡30min,加热至沸腾,保持微沸60min,压滤,在药渣中加入其质量5倍量蒸馏水依法再次煎煮30min,合并2次煎出液,真空浓缩后置50℃水浴锅中缓慢蒸发、浓缩,得山楂提取物,于4℃冰箱保存备用。Take 100g of hawthorn and put it in a beaker, add an appropriate amount of distilled water to immerse the medicinal materials, soak for 30 minutes, heat to boiling, keep slightly boiling for 60 minutes, filter by pressure, add 5 times its mass of distilled water to the medicinal residues and decocted again for 30 minutes according to the law, combine and decocted for 2 times. The solution was vacuum concentrated and then placed in a 50°C water bath to slowly evaporate and concentrate to obtain the hawthorn extract, which was stored in a 4°C refrigerator for later use.
枸杞提取物的制备过程如下:The preparation process of wolfberry extract is as follows:
取枸杞50g置烧杯中,加适量蒸馏水浸没药材,浸泡30min,加热至沸腾,保持微沸60min,过滤,在药渣中加入其质量4倍量蒸馏水依法再次煎煮30min,合并2次煎出液,真空浓缩后置50℃水浴锅中缓慢蒸发浓缩,得枸杞提取物,于4℃冰箱保存备用。Take 50g of wolfberry and put it in a beaker, add an appropriate amount of distilled water to immerse the medicinal materials, soak for 30 minutes, heat to boiling, keep a slight boil for 60 minutes, filter, add 4 times its mass of distilled water to the medicinal residues and cook again for 30 minutes according to law, and combine the 2 decoctions , vacuum concentrated and then placed in a 50°C water bath to slowly evaporate and concentrate to obtain Lycium barbarum extract, which was stored in a 4°C refrigerator for later use.
实施例2Example 2
使用实施例1所述制备工艺制备中药组合物,各原料的质量按生料计比例如下:见血清1000:决明子100:山楂10:枸杞5,中药组合物中的见血请提取物为氯仿部分分离得到的总生物碱。Using the preparation process described in Example 1 to prepare a traditional Chinese medicine composition, the proportions of the raw materials are as follows: See serum 1000: Cassia 100: Hawthorn 10: Lycium barbarum 5, and the blood-seeing extract in the traditional Chinese medicine composition is the chloroform part isolated total alkaloids.
实施例3Example 3
使用实施例1所述制备工艺制备中药组合物,各原料的质量按生料计比例如下:见血清1000:决明子400:山楂200:枸杞100,中药组合物中的见血请提取物为氯仿部分分离得到的总生物碱。Using the preparation process described in Example 1 to prepare a traditional Chinese medicine composition, the proportions of the raw materials are as follows: See serum 1000: Cassia seed 400: Hawthorn 200:
实施例4Example 4
使用实施例1所述制备工艺制备中药组合物,各原料的质量按生料计比例如下:见血清1000:决明子800:山楂400:枸杞200,中药组合物中的见血请提取物为氯仿部分分离得到的总生物碱。Using the preparation process described in Example 1 to prepare a traditional Chinese medicine composition, the proportions of the raw materials are as follows: See serum 1000: Cassia seed 800: Hawthorn 400:
实施例5Example 5
使用实施例1所述制备工艺制备中药组合物,各原料的质量按生料计比例如下:见血清1000:决明子1200:山楂600:枸杞300,中药组合物中的见血请提取物为氯仿部分分离得到的总生物碱。Using the preparation process described in Example 1 to prepare a traditional Chinese medicine composition, the proportions of the raw materials are as follows: see serum 1000: cassia 1200: hawthorn 600: wolfberry 300, the see blood extract in the traditional Chinese medicine composition is the chloroform part isolated total alkaloids.
实施例6Example 6
使用实施例1所述制备工艺制备中药组合物,各原料的质量按生料计比例如下:见血清1000:决明子1600:山楂800:枸杞400,中药组合物中的见血请提取物为氯仿部分分离得到的总生物碱。Using the preparation process described in Example 1 to prepare a traditional Chinese medicine composition, the proportions of the raw materials are as follows: See serum 1000: Cassia seed 1600: Hawthorn 800: Lycium barbarum 400, the See Blood Extract in the traditional Chinese medicine composition is the chloroform part isolated total alkaloids.
实施例7Example 7
使用实施例1所述制备工艺制备中药组合物,各原料的质量按生料计比例如下:见血清1000:决明子2000:山楂1000:枸杞500,中药组合物中的见血请提取物为氯仿部分分离得到的总生物碱。Using the preparation process described in Example 1 to prepare a traditional Chinese medicine composition, the proportions of the raw materials are as follows: See serum 1000: Cassia 2000: Hawthorn 1000:
实施例8Example 8
挑选80只实验用小鼠,将其10只一组分为八组,其中两组为空白组,三组为见血清提取物实验组,三组为中药组合物1(实施例1制备得到)实验组,见血清提取物实验组和中药组合物1实验组均分为低剂量组、中剂量组和高剂量组;80 experimental mice were selected, and 10 of them were divided into eight groups, wherein two groups were blank groups, three groups were experimental groups of serum extracts, and three groups were Chinese medicine composition 1 (prepared in Example 1) Experimental group, see serum extract experimental group and traditional
一,进行适应性喂养One, adaptive feeding
在标准实验室环境下对小鼠进行环境适应性喂养3-5天,然后进行称重,取小鼠尾尖血,离心取血清,使用全自动生化分析仪测定小鼠的甘油三酯(TG)含量、低密度脂蛋白胆固醇(LDLC)含量和高密度脂蛋白胆固醇(HDLC)含量。The mice were fed environmentally adaptive feeding for 3-5 days in a standard laboratory environment, and then weighed, the tail tip blood was collected, and the serum was collected by centrifugation. ), low-density lipoprotein cholesterol (LDLC), and high-density lipoprotein cholesterol (HDLC).
二、实验2. Experiment
其中空白组1使用基础饲料、饮用水喂养,用生理盐水灌胃,生理盐水用量按小鼠质量计0.3mL/10g。The
空白组2使用高脂饲料、饮用水喂养,所述高脂饲料由各物质按以下质量百分数混合而成:基础饲料75%、蛋白粉15%、猪油10%,用生理盐水灌胃,生理盐水用量按小鼠质量计0.3mL/10g。The
见血清提取物实验组均使用高脂饲料、饮用水喂养,所述高脂饲料由各物质按以下质量百分数混合而成:基础饲料75%、蛋白粉15%、猪油10%,用见血清提取物灌胃,见血清提取物用量按小鼠质量计0.3mL/10g;其中低剂量组使用的见血清提取物浓度为20μg/mL,中剂量组见血清提取物浓度为50μg/mL,高剂量组见血清提取物浓度为100μg/mL,所述见血清提取物为实施例1制备的未经分离纯化的萃取物。See serum extract experimental groups were fed with high-fat feed and drinking water. The extract was administered by gavage, and the dosage of serum extract was 0.3mL/10g according to the mass of mice; the concentration of serum extract used in the low-dose group was 20 μg/mL, the concentration of serum extract in the middle-dose group was 50 μg/mL, and the concentration of serum extract used in the middle-dose group was 50 μg/mL. The concentration of the serum extract in the dosage group was 100 μg/mL, and the serum extract was the unseparated and purified extract prepared in Example 1.
中药组合物1实验组均使用高脂饲料、饮用水喂养,所述高脂饲料由各物质按以下质量百分数混合而成:基础饲料75%、蛋白粉15%、猪油10%,用中药组合物1灌胃,中药组合物1用量按小鼠质量计0.3mL/10g;其中低剂量组使用的中药组合物1浓度为20μg/mL,中剂量组中药组合物1浓度为50μg/mL,高剂量组中药组合物1浓度为100μg/mL。Traditional
按照上述方法饲养28天,每3天称重一次,实验前一天禁水禁食,末次给药2h后称重、心脏取血,离心取血清,使用全自动生化分析仪测定小鼠的甘油三酯(TG)含量、低密度脂蛋白胆固醇(LDLC)含量和高密度脂蛋白胆固醇(HDLC)含量。Raised for 28 days according to the above method, weighed once every 3 days, fasted without water the day before the experiment, weighed 2 hours after the last administration, blood was collected from the heart, and serum was collected by centrifugation. Esters (TG) content, low density lipoprotein cholesterol (LDLC) content and high density lipoprotein cholesterol (HDLC) content.
由空白组1和空白组2可知使用高脂饲料喂养小鼠会使其血压和血脂存在明显提高,使用见血清提取物处理小鼠后,小鼠的血压和血脂有一定下降,但作用效果不明显,且小鼠出现食欲下降、体重降低、腹泻等症状,随着见血清提取物浓度的升高,其降血压、降血脂效果有些许提升,但副作用也更加明显;使用中药组合物1处理小鼠后,小鼠的血压、血脂有明显降低,且作用效果与中药组合物1的浓度呈正比,极个别小鼠出现了食欲降低的症状,但对体重影响不大,且没有出现腹泻。It can be seen from
实施例9Example 9
1、降血脂活性测定1. Determination of hypolipidemic activity
通过体外测定HepG2细胞中甘油三酯和胆固醇含量,来测定中药组合物的降血脂活性。The blood lipid-lowering activity of the traditional Chinese medicine composition was determined by measuring the triglyceride and cholesterol contents in HepG2 cells in vitro.
(1)细胞培养(1) Cell culture
将HepG2细胞置于高糖DMEM培养基中,在37℃、5%CO2的细胞培养箱中培养,高糖DMEM培养基中含有10%胎牛血清、100μg/mL青霉素和100μg/mL链霉素。HepG2 cells were placed in high-glucose DMEM medium containing 10% fetal bovine serum, 100 μg/mL penicillin, and 100 μg/mL streptavidin at 37 °C in a cell incubator with 5% CO . white.
(2)实施例1制得的中药组合物1、中药组合物2对HepG2细胞活力的影响实验(2) Influence experiment of
首先对HepG2细胞进行预处理:First pre-treat HepG2 cells:
HepG2细胞经胰酶消化后,以3×105个/孔接种到96孔板中,在37℃下孵育24h,孵育结束后移除细胞上清液,用含有不同质量浓度的中药组合物1、中药组合物2、含不同摩尔浓度油酸的生长培养基在37℃下继续孵育24h。After HepG2 cells were trypsinized, 3×10 5 cells/well were seeded into 96-well plates, and incubated at 37°C for 24 h. After the incubation, the cell supernatant was removed, and the cells containing different concentrations of
中药组合物1、中药组合物2的质量浓度分别为0、10μg/mL、50μg/mL、100μg/mL、200μg/mL、500μg/mL,油酸的摩尔浓度分别为0.125mmol/L、0.25mmol/L、0.5mmol/L、1.0mmol/L、2.0mmol/L。The mass concentrations of
活力测定:取中药组合物1、中药组合物2或油酸处理后的HepG2细胞,移除细胞上清液,每孔中注入100μL质量浓度为0.05g/mL噻唑蓝溶液,在37℃下继续孵育30min,然后用PBS洗涤HepG2细胞两次,在每孔中加入100μL二甲亚砜溶出细胞内的甲瓒,振荡20min后,在50nm波长处测量二甲亚砜溶液的光密度值。Viability assay: Take the HepG2 cells treated with
以不加中药组合物和油酸的为对照组,以二甲亚砜为溶剂空白作为对照。Taking no traditional Chinese medicine composition and oleic acid as the control group, taking dimethyl sulfoxide as the solvent blank as the control.
实验结果:如图1所示在质量浓度0~500μg/mL范围内,中药组合物1和中药组合物2对胰酶活性有不同程度的抑制作用,其中中药组合物1对胰脂肪酶活性的抑制较强,且随着质量浓度的增大,抑制效果有明显的提高。Experimental results: As shown in Figure 1, in the mass concentration range of 0-500 μg/mL, the traditional
如图2所示,使用含有油酸的生长培养基处理HepG2细胞后,对HepG2细胞活性有明显的抑制作用,且油酸浓度过高时对HepG2细胞有较大的毒性,油酸摩尔浓度为0.125-0.5mmol/L时培养细胞最佳。As shown in Figure 2, after treating HepG2 cells with oleic acid-containing growth medium, the activity of HepG2 cells was significantly inhibited, and when the concentration of oleic acid was too high, it was more toxic to HepG2 cells. The molar concentration of oleic acid was 0.125-0.5mmol/L cultured cells is the best.
(3)实施例1制得的中药组合物1、中药组合物2对高脂HepG2细胞模型甘油三酯合成的影响实验(3) Influence experiment of
将中药组合物1或2溶解于摩尔浓度为10-2M的DMSO中,稀释到10-5M,取HepG2细胞以3×105个/孔接种至96孔板,待其贴壁,用不含中药组合物的DMEM培养基洗涤HepG2细胞后,用含有不同质量浓度(0、10μg/mL、50μg/mL、100μg/mL、200μg/mL、500μg/mL)中药组合物1或中药组合物2的DMEM培养基,在37℃下孵育12h,然后去除细胞上清液,用含油酸的诱导培养基继续培养24h,以DMEM培养基培养36h的正常HepG2细胞为空白组。Dissolve the traditional
孵育结束后,用PBS轻轻洗涤3次,然后用RIPA裂解液在冰浴下裂解细胞30min,再在4℃、10000rpm下离心15min,取上清液,用BCA蛋白检测试剂盒测定细胞蛋白质含量,使用甘油三酯检测试剂盒测定上清液中甘油三酯含量,结果以蛋白质量计。After the incubation, the cells were gently washed with PBS for 3 times, then the cells were lysed with RIPA lysis solution in an ice bath for 30 min, and then centrifuged at 4 °C and 10000 rpm for 15 min. , and the triglyceride content in the supernatant was determined using a triglyceride detection kit, and the result was calculated as the amount of protein.
实验结果:如图3所示,与空白组对照结果相比,经中药组合物1和中药组合物2处理后,油酸诱导的高脂HepG2细胞模型甘油三酯的含量均有降低,这表明中药组合物1和中药组合物2对高脂HepG2细胞中甘油三酯的合成均具有抑制作用,其中中药组合物1对高脂HepG2细胞中甘油三酯合成的抑制活性最强。Experimental results: As shown in Figure 3, compared with the control results of the blank group, the content of triglycerides in the high-fat HepG2 cell model induced by oleic acid was reduced after treatment with
(4)实施例1制得的中药组合物1对高胆固醇HepG2细胞模型中脂类合成的影响实验(4) Influence experiment of traditional
将中药组合物1溶解于摩尔浓度为10-2M的DMSO中,稀释到10-5M,所述DMSO用作溶剂,有助于中药组合物1的渗透,同时也是一种渗透性保护剂,取HepG2细胞以3×105个/孔接种至96孔板,待其贴壁,移除细胞上清液,用含有不同质量浓度(0、10μg/mL、50μg/mL、100μg/mL、200μg/mL、500μg/mL)中药组合物1的DMEM培养基于37℃孵育12h,去除细胞上清液,再用含胆固醇的诱导培养基继续培养24h,用DMEM培养基培养12h,去除细胞上清液,再用含15mg/mL胆固醇和0.2mg/mL辛伐他汀的培养基继续培养24h的细胞为辛伐他汀阳性对照组。The traditional
孵育结束后,用PBS轻轻洗涤细胞3次,用RIPA裂解液在冰浴下裂解细胞30min,在4℃、10000rpm下离心15min,取上清液,用BCA蛋白检测试剂盒测定细胞蛋白含量,用总胆固醇检测试剂盒测定HepG2细胞中总胆固醇含量,结果以蛋白质质量计。After the incubation, the cells were gently washed with PBS for 3 times, and the cells were lysed with RIPA lysis solution in an ice bath for 30 min, centrifuged at 4°C and 10,000 rpm for 15 min, and the supernatant was collected. The content of total cholesterol in HepG2 cells was measured with a total cholesterol detection kit, and the results were calculated as protein quality.
实验结果:根据上述实验结果选取对高脂HepG2细胞模型甘油三酯的抑制作用最强的中药组合物1,进行高胆固醇HepG2细胞模型中脂类合成的影响实验,如图4所示,与空白对照相比,0.2mg/mL的辛伐他汀和中药组合物1都能够使HepG2细胞模型中总胆固醇的含量明显降低,这表明辛伐他汀和中药组合物1可有效抑制高胆固醇HepG2细胞模型中脂类合成,且随着中药组合物1浓度的增加,其对高胆固醇HepG2细胞模型中脂类合成的抑制活性也逐渐增加,在其质量浓度为500μg/mL时抑制效果最好。Experimental results: According to the above experimental results, the traditional
(5)实施例2-7制得的中药组合物对HepG2细胞活力的影响实验(5) Influence experiment of the traditional Chinese medicine composition prepared in Example 2-7 on the viability of HepG2 cells
HepG2细胞经胰酶消化后,以3×105个/孔接种到96孔板中,在37℃下孵育24h,孵育结束后移除细胞上清液,分别用含有实施例2-7制备的中药组合物的生长培养基在37℃下继续孵育24h,每个实施例制备的中药组合物设5组实验组,其中中药组合物的质量浓度分别为0、10μg/mL、50μg/mL、100μg/mL、200μg/mL、500μg/mL;After HepG2 cells were trypsinized, 3×10 5 cells/well were seeded into 96-well plates, incubated at 37°C for 24 h, and the cell supernatant was removed after the incubation. The growth medium of the traditional Chinese medicine composition was incubated at 37°C for 24 hours. The traditional Chinese medicine composition prepared in each example was set up in 5 experimental groups, and the mass concentrations of the traditional Chinese medicine composition were 0, 10 μg/mL, 50 μg/mL, and 100 μg respectively. /mL, 200μg/mL, 500μg/mL;
活力测定:取中药组合物处理后的HepG2细胞,移除细胞上清液,每孔中注入100μL质量浓度为0.05g/mL噻唑蓝溶液,在37℃下继续孵育30min,然后用PBS洗涤HepG2细胞两次,在每孔中加入100μL二甲亚砜溶出细胞内的甲瓒,振荡20min后,在50nm波长处测量二甲亚砜溶液的光密度值,获得各实验组中中药组合物对胰脂肪酶活性的抑制数据,如表1所示:Viability assay: Take the HepG2 cells treated with the traditional Chinese medicine composition, remove the cell supernatant, inject 100 μL of 0.05 g/mL thiazole blue solution into each well, continue to incubate at 37 °C for 30 min, and then wash the HepG2 cells with PBS Twice, 100 μL of dimethyl sulfoxide was added to each well to dissolve the formazan in the cells. After shaking for 20 min, the optical density of the dimethyl sulfoxide solution was measured at a wavelength of 50 nm to obtain the effect of traditional Chinese medicine compositions on pancreatic fat in each experimental group. The inhibition data of enzymatic activity are shown in Table 1:
表1中药组合物对胰脂肪酶活性的抑制数据Table 1 Inhibitory data of traditional Chinese medicine composition on pancreatic lipase activity
实施例10Example 10
称取中药组合物1 100g、糊精50g、羧甲基纤维素钠10g、硬脂酸镁2g,将各物质混匀后过80目筛,使用干式制粒机制粒,用60目筛整粒后灌于胶囊中制得中药组合物胶囊,其中糊精用作赋形剂和填充剂,羧甲基纤维素钠用作增稠剂,硬脂酸镁用作助流剂。
实施例11Example 11
称取中药组合物1 100g、糊精30g、羧甲基纤维素钠10g、羟丙基纤维素钠20g、硬脂酸镁2g,将各物质混匀后过80目筛,使用干式制粒机制粒,用60目筛整粒、压片、包衣得到中药组合物片剂,其中糊精用作赋形剂和填充剂,羧甲基纤维素钠用作增稠剂,羟丙基纤维素钠作为片剂的薄膜衣材料和粘合剂,硬脂酸镁在压片中用作助流剂,上述添加剂用量过少会造成压片过程中片剂成型不稳,影响片剂的质量,过多会影响片剂中见血清提取物的含量,降低片剂的药效。
将100名志愿者分为三个组别,前40名志愿者服用实施例11制备的中药组合物片剂,每日三次,每次2-4片,第41名至第80名志愿者服用实施例10制备的中药组合物胶囊,每日三次,每次2-4粒,第81名至第100名志愿者服用实施例1制备的中药组合物1 100g,每日三次,每次2-4份,连续服药治疗观察一年,实验分组和有效性参数如表2所示,其中显效88例,有效12例,所有志愿者的高血压、高血脂症状均得到了很好的缓解,服药前后患者的血脂数据如表3所示,应用患者中未见明显毒副作用,极个别胃寒者出现轻微腹泻,可同时食用大枣等性温药食纠正,由表3可知服用本实施例所述中药组合物1及其制成的片剂、胶囊,均能有效降低患者的血压和血脂,且作用过程温和,副作用较小。The 100 volunteers were divided into three groups, the first 40 volunteers took the traditional Chinese medicine composition tablets prepared in Example 11, three times a day, 2-4 tablets each time, and the 41st to 80th volunteers took The capsules of the traditional Chinese medicine composition prepared in Example 10, three times a day, 2-4 capsules each time, the 81st to the 100th volunteers took the traditional
表2实验分组和有效性参数Table 2 Experimental grouping and validity parameters
表3实验前后志愿者的血压、血脂值Table 3 Blood pressure and blood lipid values of volunteers before and after the experiment
见血清属于寒性中草药,化学成分复杂,未经过分离纯化直接将其用于降血压、降血脂,会对胃肠道造成刺激,特别是胃肠功能较弱的人群,严重时会出现恶心、呕吐等症状,还可能导致食欲下降、腹泻等,且降血压、降血脂效果不显著,见效慢,本实施例通过上述方法分离提纯得到见血清中的有效成分—总生物碱,并提取决明子中的蒽醌类成分,包括大黄酚、大黄素甲醚、决明素、橙黄决明素等,辅以山楂、枸杞的全成分提取物,复配得到中药组合物,决明子具有缓泻作用,山楂提取物含有丰富的果酸和有机酸,能刺激消化液分泌,改善人体脾胃功能,缓解腹泻、食欲不振等症状,枸杞提取物除滋阴补肾、安神功效外,还因其含有枸杞多糖,具有双向调节血糖的作用;综上,本实施例提供的中药组合物中各物质的作用效果能相辅相成,在短时间内实现降血脂血压的功效,同时避免了因无效成分、刺激成分等带来的副作用,经自愿者验证,本实施例所述中药组合物的降血压、降血脂效果极其显著,能在2周内使自愿者恢复正常血压,且在停药2个月内不反弹。See serum is a cold Chinese herbal medicine with complex chemical composition. It is directly used for lowering blood pressure and blood lipid without separation and purification, which will cause irritation to the gastrointestinal tract, especially for people with weak gastrointestinal function. Symptoms such as vomiting may also lead to decreased appetite, diarrhea, etc., and the effect of lowering blood pressure and blood lipid is not significant, and the effect is slow. The anthraquinones, including chrysophanol, emodin methyl ether, cassia, orange cassia, etc., supplemented by the full-component extracts of hawthorn and wolfberry, are compounded to obtain a traditional Chinese medicine composition. Cassia has a laxative effect, and hawthorn extracts The extract is rich in fruit acids and organic acids, which can stimulate the secretion of digestive juice, improve the function of the human spleen and stomach, and relieve symptoms such as diarrhea and loss of appetite. In addition to the effects of nourishing yin, invigorating the kidney, and soothing the nerves, the wolfberry extract also contains wolfberry polysaccharide, which has a two-way The effect of regulating blood sugar; To sum up, the effects of the various substances in the traditional Chinese medicine composition provided in this embodiment can complement each other, realize the effect of lowering blood lipid and blood pressure in a short time, and avoid the side effects caused by ineffective ingredients, stimulating ingredients, etc. , verified by volunteers, the blood pressure and blood lipid lowering effect of the traditional Chinese medicine composition described in this example is extremely significant, and it can restore normal blood pressure in volunteers within 2 weeks, and does not rebound within 2 months of drug withdrawal.
本说明书中的各个实施例均采用相关的方式描述,各个实施例之间相同相似的部分互相参见即可,每个实施例重点说明的都是与其他实施例的不同之处。尤其,对于系统实施例而言,由于其基本相似于方法实施例,所以描述的比较简单,相关之处参见方法实施例的部分说明即可。Each embodiment in this specification is described in a related manner, and the same and similar parts between the various embodiments may be referred to each other, and each embodiment focuses on the differences from other embodiments. In particular, for the system embodiments, since they are basically similar to the method embodiments, the description is relatively simple, and for related parts, please refer to the partial descriptions of the method embodiments.
以上所述仅为本发明的较佳实施例而已,并非用于限定本发明的保护范围。凡在本发明的精神和原则之内所作的任何修改、等同替换、改进等,均包含在本发明的保护范围内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention are included in the protection scope of the present invention.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210250536.3A CN114470101A (en) | 2022-03-15 | 2022-03-15 | Traditional Chinese medicine composition and preparation method thereof, and oral preparation containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210250536.3A CN114470101A (en) | 2022-03-15 | 2022-03-15 | Traditional Chinese medicine composition and preparation method thereof, and oral preparation containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114470101A true CN114470101A (en) | 2022-05-13 |
Family
ID=81486899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210250536.3A Pending CN114470101A (en) | 2022-03-15 | 2022-03-15 | Traditional Chinese medicine composition and preparation method thereof, and oral preparation containing the same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114470101A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115671203A (en) * | 2022-11-24 | 2023-02-03 | 广州中医药大学科技产业园有限公司 | Traditional Chinese medicine compound extract for reducing blood sugar and blood fat and extraction method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739599A (en) * | 2005-09-12 | 2006-03-01 | 周然 | Blood fat reducing and liver protecting medicine prepared with cassia seed extract |
CN102274403A (en) * | 2011-08-09 | 2011-12-14 | 南京泽朗医药科技有限公司 | Method for extracting total alkaloids from liparis nervosa |
CN104893926A (en) * | 2015-06-29 | 2015-09-09 | 铜川市药师佛养生酒业有限公司 | Well-being healthcare medicated wine and preparation method thereof |
-
2022
- 2022-03-15 CN CN202210250536.3A patent/CN114470101A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739599A (en) * | 2005-09-12 | 2006-03-01 | 周然 | Blood fat reducing and liver protecting medicine prepared with cassia seed extract |
CN102274403A (en) * | 2011-08-09 | 2011-12-14 | 南京泽朗医药科技有限公司 | Method for extracting total alkaloids from liparis nervosa |
CN104893926A (en) * | 2015-06-29 | 2015-09-09 | 铜川市药师佛养生酒业有限公司 | Well-being healthcare medicated wine and preparation method thereof |
Non-Patent Citations (5)
Title |
---|
张仁强 等: "草药见血清中化学物质的提取及医用功效探讨", 《教育教学论坛》 * |
张晓路 等: "决明子中总蒽醌苷元的大孔吸附树脂纯化工艺的研究", 《中草药》 * |
徐岩 等: "中西医结合治疗高脂血症疗效观察", 《辽宁中医杂志》 * |
朱彩燕: "决明子中大黄素的提取、分离和纯化方法的研究", 《中国现代药物应用》 * |
李国平 等: "见血清总生物碱提取工艺的优化", 《武夷学院学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115671203A (en) * | 2022-11-24 | 2023-02-03 | 广州中医药大学科技产业园有限公司 | Traditional Chinese medicine compound extract for reducing blood sugar and blood fat and extraction method thereof |
CN115671203B (en) * | 2022-11-24 | 2023-10-27 | 广州中医药大学科技产业园有限公司 | A Chinese medicinal compound extract for lowering blood sugar and blood lipid, and its extraction method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101463061B (en) | Ginseng saponin Rg1 and Rb1 in pseudo-ginseng and preparation of total saponin thereof | |
CN104910240B (en) | Triterpene saponins in Bougainvillea glabra, hypoglycemic drug using it as an active ingredient, and preparation method and application thereof | |
CN103040882B (en) | Passiflora edulis sims stem-leaf extract as well as pharmaceutical composition and antidepressant action of extract | |
CN101229335A (en) | Method for Enzymatically Preparing Smilax Smilax Total Saponins Extract | |
CN107118219B (en) | The method of separating-purifying gelsevirine, koumidine, koumine, gelsemine and furans koumine from elegant jessamine | |
CN109602759B (en) | Application of podocarpus macrophyllus polysaccharide | |
CN107929337A (en) | A kind of preparation method and application of Panax stipuleanatus Tsai et Feng anti-inflammatory active component | |
CN114470101A (en) | Traditional Chinese medicine composition and preparation method thereof, and oral preparation containing the same | |
CN113999272A (en) | Preparation method and application of melissoside | |
CN105640971B (en) | Application of the total saposins in terms of preparing auxiliary hyperglycemic drug in prematurity Fructus Monordicae extract | |
CN115010618B (en) | A kind of uric acid-lowering golden amide alcohol ester separation and purification method and application thereof | |
CN108904521B (en) | A kind of antitumor drug containing Baiwei ginseng polysaccharide and using method thereof | |
CN112168932A (en) | Traditional Chinese medicine composition and extract for preventing new coronary pneumonia, and preparation method and application thereof | |
CN108129542A (en) | C-3,28,29- tri- replaces oleanane triterpene saponin and its pharmaceutical composition | |
CN105193824B (en) | A kind of ganodenic acid acid activity position and its preparation method and application | |
CN111329866B (en) | Application of pentacyclic triterpenoid in preparation of anti-migraine medicine | |
CN104353057B (en) | Blood-pressure reducing health care product containing european bird cherry anthocyanogen | |
CN107648311B (en) | Composition and medicine with antiviral and antiinflammatory effects | |
CN111700927A (en) | A kind of medicine and food homologous composition with hypoglycemic effect and its preparation method and application | |
CN112618560A (en) | Pharmaceutical composition containing ginsenoside and application thereof in reducing blood fat and inhibiting fatty liver | |
CN105796637A (en) | Anti-breast cancer traditional Chinese medicine composition as well as preparation method and application thereof | |
CN105326872A (en) | Preparation method for herba patriniae extract with therapeutical effect on ulcerative colitis | |
CN105456277A (en) | Application of active part of ganoderma triterpene acid in preparing hypolipidemic health care products and drugs | |
CN102138947B (en) | Propolis Chinese medicinal composition | |
CN104906214B (en) | The combined preparation process of flavonoids and triterpene acid in a kind of loguat leaf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |